Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 22, 2013

View Archived Issues

Role for cannabinoid CB2 receptor signaling in Huntington's disease

MCT 1 linked to 3-bromopyruvate uptake and sensitivity in cancer cells

U.S. researchers present new vitamin D receptor ligands

Bristol-Myers Squibb prepares novel PDE10A inhibitors

University of Florida patents new interferon mimetic peptides

Alnylam Pharmaceuticals divulges new siRNAs

Nihon Medi-Physics presents new Alzheimer's disease diagnostics

New alpha7 nAChR positive allosteric modulators synthesized by Dainippon Sumitomo Pharma

Acorda Therapeutics reviews pipeline

Bristol-Myers Squibb studies BMS-986020 for IPF in phase II trial

Dainippon Sumitomo Pharma seeks Japanese approval for Meropen dosage

Amunix enters into licensing agreement with Janssen Biotech

FDA issues complete response letter for Rytary NDA

Novartis receives positive CHMP opinion for Ilaris in acute gouty arthritis

Results from a semiqualitative validation of [18F]-NAV-4694 imaging

Eisai begins recruiting patients in phase II study of Alzheimer's disease treatment candidate

Tresiba and Ryzodeg approved for diabetes in Europe

Array BioPharma presents update on ongoing projects

CSL Behring enrolls first patient in global phase III pediatric study of rIX-FP

Global phase I study of AZD-1208 commences

Translation research centers establish drug discovery and development alliance

BioCad advances development of Extimia for neutropenia

Second milestone achieved in Genfit's metabolic disorder collaboration with Sanofi

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 9, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Brenig Therapeutics discovers new LRRK2 inhibitors
BioWorld Science
Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for...